Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study
Authors:
- Elyse LeeVanELElyse LeeVan
- Amanda L. SkarlupkaASAmanda L. Skarlupka
- Christos PatriotisCPChristos Patriotis
- Wendy S. RubinsteinWRWendy S. Rubinstein
- Paul F. PinskyPPPaul F. Pinsky
- Wade BoltonWBWade Bolton
- Anthony DickherberADAnthony Dickherber
- Daniel C. EdelmanDEDaniel C. Edelman
- Lyndsay N. HarrisLHLyndsay N. Harris
- Hormuzd A. KatkiHKHormuzd A. Katki
- Erin B. LavikELErin B. Lavik
- Albine MartinAMAlbine Martin
Open Access
- 4 August 2025
- journal article
- biomarkers
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (10) , 1787-1793
Abstract
Background: The Cancer Screening Research Network is a new clinical trials network funded by the NCI. The first Cancer Screening Research Network study, the Vanguard Study (VS), will assess the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials. Methods: This article describes the framework NCI developed to engage MCD assay developers, evaluate emerging technologies using biobank reference sets, and select fit-for-purpose MCD assays for inclusion in the VS. Results: NCI evaluated 23 technologically diverse MCD assays, all utilizing machine learning and artificial intelligence components. Nine assays underwent blinded performance evaluations using specimens from three biobanks. Assay developers were provided with independent assessments of their assays, which enabled them to make further assay refinements to enhance performance. The assay selection process resulted in participation by two assay companies in the VS. Conclusions: NCI created a fair and transparent process to streamline the evaluation of assay performance and to select promising assays for clinical research and public health initiatives. Impact: Significant resources are required for large-scale cancer screening trials; therefore, promising technologies must be prioritized for inclusion in a definitive trial. NCI’s assay selection framework can be used and repurposed by other networks and institutions.Keywords
This publication has 11 references indexed in Scilit:
- Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screeningJNCI: Journal of the National Cancer Institute, 2024
- Cancer screening with multicancer detection tests: A translational science reviewCA: A Cancer Journal for Clinicians, 2024
- Multicancer Early Detection Tests: An Overview of Early Results From Prospective Clinical Studies and Opportunities for OncologistsJCO Oncology Practice, 2023
- Predictive Performance of Cell-Free Nucleic Acid-Based Multi-Cancer Early Detection Tests: A Systematic ReviewClinical Chemistry, 2023
- Study design considerations for trials to evaluate multicancer early detection assays for clinical utilityJNCI: Journal of the National Cancer Institute, 2022
- Adding Rigor to Biomarker Evaluations—EDRN ExperienceCancer Epidemiology, Biomarkers & Prevention, 2020
- The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen ResourceReviews on Recent Clinical Trials, 2015
- Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of DiseaseCancer Epidemiology, Biomarkers & Prevention, 2015
- A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian CancerCancer Prevention Research, 2011
- Phases of Biomarker Development for Early Detection of CancerJNCI: Journal of the National Cancer Institute, 2001